UniProtKB/SwissProt variant VAR

Variant information

Variant position:

154

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

US

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Isoleucine (I) at position 154 (V154I, p.Val154Ile).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic.

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

3

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

Found in patients with alcohol-responsive myoclonus-dystonia; unknown pathological significance; the mutation does not affect functional properties.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs104894220 [ dbSNP | Ensembl ]

Sequence information

Variant position:

154

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

443

The length of the canonical sequence.

Location on the sequence:

TAVAMPMLYNTRYSSKRRVT V MISIVWVLSFTISCPLLFGL

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGL

                              TAVAMPMLYNTRYSSKRRVTVMIAIVWVLSFTISCPLLFGL

Chimpanzee                    TAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGL

Mouse                         TAVAMPMLYNTRYSSKRRVTVMIAIVWVLSFTISCPLLFGL

Rat                           TAVAMPMLYNTRYSSKRRVTVMIAIVWVLSFTISCPLLFGL

Bovine                        TAVAMPMLYNTRYSSKRRVTVMIAIVWVLSFTISCPMLFGL

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 443	D(2) dopamine receptor
Transmembrane	152 – 172	Helical; Name=4
Disulfide bond	107 – 182
Helix	145 – 172

Literature citations

Association of a missense change in the D2 dopamine receptor with myoclonus dystonia.
Klein C.; Brin M.F.; Kramer P.; Sena-Esteves M.; de Leon D.; Doheny D.; Bressman S.; Fahn S.; Breakefield X.O.; Ozelius L.J.;
Proc. Natl. Acad. Sci. U.S.A. 96:5173-5176(1999)
Cited for: VARIANT ILE-154;

Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia.
Klein C.; Gurvich N.; Sena-Esteves M.; Bressman S.; Brin M.F.; Ebersole B.J.; Fink S.; Forsgren L.; Friedman J.; Grimes D.; Holmgren G.; Kyllerman M.; Lang A.E.; de Leon D.; Leung J.; Prioleau C.; Raymond D.; Sanner G.; Saunders-Pullman R.; Vieregge P.; Wahlstrom J.; Breakefield X.O.; Kramer P.L.; Ozelius L.J.; Sealfon S.C.;
Ann. Neurol. 47:369-373(2000)
Cited for: CHARACTERIZATION OF VARIANT ILE-154;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P14416: Variant p.Val154Ile